# EDGAR Filing Document

**Accession Number:** 0001981662
**File Stem:** 0000000000-25-009839
**Filing Date:** 2025-9
**Character Count:** 6489
**Document Hash:** 713c57efeb5c41b6fa1f170917fb85d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009839.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0000000000-25-009839

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250910

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewGenIvf Group Ltd
- **CENTRAL INDEX KEY:** 0001981662
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08362

**BUSINESS ADDRESS:**
- **STREET 1:** 13/F, PS TOWER, SUKHUMVIT 21 RD (ASOKE)
- **CITY:** BANGKOK
- **STATE:** W1
- **ZIP:** 0000
- **BUSINESS PHONE:** 852-2861-1666

**MAIL ADDRESS:**
- **STREET 1:** 1/F, PIER 2, CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASPAC I Mini Acquisition Corp.
- **DATE OF NAME CHANGE:** 20230614
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-079717

## Text-Extract

```

                                                             September 10, 2025

Wing Fung Alfred Siu
Chief Executive Officer
NewGenIvf Group Ltd
36/39-36/40, 13th Floor, PS Tower
Sukhumvit 21 Road (Asoke)
Khlong Toei Nuea Sub-district
Watthana District, Bangkok 10110
Thailand

       Re: NewGenIvf Group Ltd
           Draft Registration Statement on Form F-1
           Submitted August 22, 2025
           CIK No. 0001981662
Dear Wing Fung Alfred Siu:

       We have conducted a limited review of your draft registration statement
and have the
following comments.

        Please respond to this letter by providing any requested information
and by publicly
filing your registration statement and non-public draft submission on EDGAR. If
you do not
believe a comment applies to your facts and circumstances or do not believe an
amendment is
appropriate, please tell us why in your response.

        After reviewing the information you provide in response to this letter
and your filed
registration statement, we may have additional comments.

Draft Registration Statement on Form F-1 Submitted August 22, 2025
Recent Development
Strategic Investments in Digital Assets, page 23

1.     We note your disclosure that on June 2, 2025, the Company announced
plans to invest
       up to US$30 million in staking the digital asset SOL and to fund such
investment
       using existing credit facilities. We also note your disclosure that as
of July 25, 2025,
       the Company has accumulated total SOL holdings of 6,703.99, valued at
       approximately US$1.24 million. Please revise your disclosure to address
the
       following:
           Describe more specifically what you mean by    investing $30 million
in staking
 September 10, 2025
Page 2

           the digital asset SOL    and provide an estimated timeline for your
Solana strategy
           plan.
             Discuss the material aspects of your Solana strategy plan and how
you intend to
           generate profit through this strategy, including an estimate of the
cost of each step
           and the challenges you may face, including the payment of any debt
obligations.
             Explain the custody arrangements for the SOL that you hold and
plan to hold and
           identify the third-party custodians you use or intend to use to
store these assets.
             Provide separate risk factors addressing material risks related to
your Solana
           strategy.
             Include a discussion of the SOL ecosystem and a description of the
lifecycle of
           the SOL token, including the past and current supply of SOL, how new
SOL is
           created, any burn mechanism, the bonding and unbonding period, and
any
           inflationary or deflationary mechanism.
Risk Factors
Risks Related to Government Regulation
Advertising or offering of gender selection services in certain jurisdictions
in which
NewGenIvf operates..., page 49

2.     We note your risk factor disclosure regarding certain risks to your
business if you,
       your representatives, or your sub-contractors inadvertently violate, or
are alleged to
       violate, laws prohibiting gender selection for non-medical purposes such
as the Hong
       Kong Human Reproductive Technology Ordinance. We also note your
statement that
       you derive "a substantial portion of [your] revenue from Chinese clients
and as such,
       [your] maintenance of PRC-sourced revenues and access to new and
existing clients
       from the PRC are also subject to the economic conditions of China."
Recent media
       stories have reported on the arrests of various individuals in Hong Kong
for alleged
       violations of the Human Reproductive Technology Ordinance based on
alleged
       advertisement, promotion and solicitation of gender selection services
to customers in
       Hong Kong. Please expand on your disclosure to explain the extent you
have been, or
       expect to be, materially impacted by any such increased enforcement of
the Hong
       Kong Human Reproductive Technology Ordinance. Your disclosure should
address
       whether there has been any material impact on your ability to generate
revenue from
       Chinese clients. Please also clarify whether the Company's PRC-sourced
revenues are
       derived from clients in mainland China and/or Hong Kong.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       We also remind you that your registration statement and non-public draft
submission
must be on file at least two business days prior to the requested effective
date and time. Refer
to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to
review any amendment prior to the requested effective date of the registration
statement.

       Please contact Conlon Danberg at 202-551-4466 or Lauren Nguyen at
202-551-3642
 September 10, 2025
Page 3

with any other questions.

                            Sincerely,

                            Division of Corporation Finance
                            Office of Industrial Applications and
                            Services
cc:   Steve Lin

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._